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Background: Mefloquine is an anti-malarial drug that can have neurological side effects. This study examines how
mefloquine (MF) influences central nervous control of autonomic and respiratory systems using the arterially
perfused working heart brainstem preparation (WHBP) of the rat. Recordings of nerve activity were made from the
thoracic sympathetic chain and phrenic nerve, while heart rate (HR) and perfusion pressure were also monitored in
the arterially perfused, decerebrate, rat WHBP. MF was added to the perfusate at 1 μM to examine its effects on
baseline parameters as well as baroreceptor and chemoreceptor reflexes.
Results: MF caused a significant, atropine resistant, bradycardia and increased phrenic nerve discharge frequency.
Chemoreceptor mediated sympathoexcitation (elicited by addition of 0.1 ml of 0.03% sodium cyanide to the aortic
cannula) was significantly attenuated by the application of MF to the perfusate. Furthermore MF significantly
decreased rate of return to resting HR following chemoreceptor induced bradycardia. An increase in respiratory
frequency and attenuated respiratory-related sympathetic nerve discharge during chemoreceptor stimulation was
also elicited with MF compared to control. However, MF did not significantly alter baroreceptor reflex sensitivity.
Conclusions: These studies indicate that in the WHBP, MF causes profound alterations in autonomic and
respiratory control. The possibility that these effects may be mediated through actions on connexin 36 containing
gap junctions in central neurones controlling sympathetic nervous outflow is discussed.
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Mefloquine (MF) is an anti-malarial drug which has
been widely used for the treatment of malaria. Since MF
has an elimination half life of between 14 to 41 days [1],
it has been a common choice as a malaria prophylaxis
drug. However, MF can clearly influence the central ner-
vous system since patients taking MF as an anti-malarial
report neuropsychiatric adverse reactions which include
anxiety, strange and vivid dreams, hallucinations, psych-
osis [2,3].
In addition to neuropsychiatric effects, patients taking
MF as an anti-malarial exhibited a significant bradycar-
dia 6 days after administration [4]. They reported that
the bradycardia observed may have been as a result of* Correspondence: j.deuchars@leeds.ac.uk
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reproduction in any medium, provided the orautonomic dysfunction rather than an effect on the heart
itself since the PR-interval, QRS-interval and QTc inter-
vals were not affected by this dose. Furthermore, severe
postural orthostatic tachycardia syndrome including
symptoms of palpitations and dizziness, loss of R-R
interval variation, typical of autonomic dysfunction, were
reported in a case study of a woman taking MF as an
anti-malarial [5]. MF may have further consequences, as
respiratory complications including dyspnoea and re-
spiratory distress have been ascribed to MF in case stud-
ies of patients treated for malaria [6,7].
This study aims to explore the neural mechanisms of
the significant cardio-respiratory side effects of MF mal-
aria treatment. Exactly how MF causes the side effects in
central autonomic circuits and on cardiovascular regula-
tion is unknown, although one possible action of MF is
through blockade of gap junctions (GJs) containing the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spinal cord contain several neuronal populations which
display electrical coupling likely to be mediated by Cx36
containing GJs, including brainstem respiratory [9] and
spinal sympathetic preganglionic neurones (SPNs) [10-12].
Since gap junction communication between neurones can
be inhibited by anaesthetics [13], experiments were con-
ducted in an anaesthetic free, arterially perfused working
heart brainstem preparation (WHBP).
Methods
Surgical procedures
18 day old, male Wistar rats were deeply anaesthetised
with halothane (3–5%) and once the animal failed to re-
spond to noxious pinch to the tail or hind paw, the ani-
mal was bisected sub-diaphragmatically. The head and
thorax were submerged in ice cold (5°C) modified artifi-
cial cerebrospinal fluid (aCSF, see below for compos-
ition) equilibrated with carbogen (95% O2, 5% CO2). The
animal was decerebrated at the precollicular level and
skinned. The dorsal surface of the brainstem was exposed
by removal of the skull and cerebellum, the brainstem
was superfused with modified aCSF. The phrenic and
sympathetic nerves were isolated and the diaphragm,
lungs and surrounding organs were removed. The des-
cending aorta was isolated and the posterior thorax and
spinal column were removed to mid thoracic level.
The preparation was transferred to a recording cham-
ber and the descending aorta cannulated and perfused
retrogradely with modified aCSF (pH 7.35 ± 0.05) at
32°C containing Ficoll 70 (Sigma-Aldrich), using a roller
pump (Watson-Marlow). The perfusate was filtered with
a nylon mesh to prevent blood clots and cellular debris
from blocking the capillary beds. Perfusate was passed
through two bubble traps which removed gas bubbles
and reduced pulsations from the roller pump and heart.
Aortic perfusion pressure was measured by a double
lumen catheter connected to a pressure transducer. The
perfusate was recycled after reoxygenation to limit loss
of washed out nutrients such as amino acids. Bath
temperature was maintained at 28°C using a heat
chamber.
Nerve recordings
To monitor central respiratory drive, recordings were
made from the central end of the cut phrenic nerve
using a glass suction electrode and the raw data
recorded using Spike 2 (Cambridge Electronic Design,
CED). Cardiac activity, recorded in the form of electro-
cardiography (ECG), returned within seconds and rhyth-
mic contractions of respiratory muscles within a few
minutes after the onset of reperfusion. Sympathetic
nerve recordings were made from the lower thoracic
sympathetic chain also using a glass suction electrode.This sympathetic activity exhibited respiratory modula-
tion in all cases. HR was derived from ECG, recorded
simultaneously with the phrenic and sympathetic nerve
recordings.
Solutions
Modified aCSF contained (in mM): NaCl, 125;
NaHCO3, 24; KCl, 5; CaCl2, 2.5; MgSO4, 1.25; KH2PO4
1.25 and D glucose, 10. In addition 1.25%, Ficoll, (type
70; Sigma Aldrich, Gillingham, UK) was added to the
perfusate. Stock solutions of atropine sulphate (1 mM in
H20, Sigma Aldrich), MF (1 Mm in dimethyl sulfoxide;
Sigma Aldrich) were prepared and aliquots were frozen
at −20°C. Prior to each experiment, aliquots were thawed
and added to the perfusate (where stated).
Autonomic reflexes
To test the effects of MF on specific reflex responses,
the preparation was subject to manipulation of the car-
diorespiratory system. Baroreceptors were stimulated by
a transient increase in perfusion pressure (by increasing
the speed of the roller pump to maximum rotation) and
chemoreceptors were activated by injection of 0.1 ml of
0.03% sodium cyanide (NaCN) into the descending aorta
(via a side arm port of the perfusion cannula).
Analysis
Signals were recorded using glass suction electrodes
attached to a head stage (Digitimer, NL100) and fed into
a Neurolog amplifier (x 1000 amplification; Digitimer,
NL900D). Signals were passed through a Humbug
(Quest Scientific, Canada) to filter out mains noise at
50/60 Hz. Recordings were bandpass filtered between
50 Hz and 4 kHz. Recordings were digitised with a sam-
pling frequency of 8 kHz and saved on computer using
an interface (CED 1401, UK) to be analysed with Spike 2
software off line.
Sympathetic nerve discharge (SND) was rectified and
integrated (
R
SND) with a time constant of 100 ms. The
difference in
R
SND from baseline to chemoreceptor/
baroreceptor stimulation was calculated in control and
in MF using a custom written Spike2 script described
previously [14].
R
SND was measured 10 seconds before
the autonomic reflex was elicited, during the response
and after the autonomic reflex stimulation. At least three
trials were elicited in each preparation during control,
MF and washout and at least 5 minutes were allowed to
elapse between each trial.
Phrenic nerve discharge (PND) was amplified and fil-
tered then integrated and rectified (time constant of
100 ms). Stable periods of baseline PND, as recorded
from Spike 2, were analysed off line to produce averages
for Ti (total inspiration) duration, Te (total expiration)
duration, Ttot (total inspiration and expiration) duration
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30 cycles per preparation. Activity was then analysed
during chemoreceptor and baroreceptor stimulation.
After such autonomic reflexes HR and PND were com-
pared during the stimulus and for 5–10 respiratory
cycles immediately following the stimulus. Three trials
per preparation were averaged.
We also measured the amplitude of rectified and inte-
grated
R
SND for the first 500 ms of the PND (start of the
augmenting phase, considered early inspiration) and
compared it to the
R
SND amplitude for the first 500 ms
of silencing of the phrenic nerve (equivalent to post-
inspiration as described by [14]). These two amplitudes
were expressed as a ratio and compared in control and
MF to give a measure of the degree of respiratory-relatedR
SND in the two conditions. During chemoreceptor




conditions was assessed by measurement of
R
SND dur-
ing either total inspiration or expiration duration.
Unless stated, data are presented as group mean ± the
standard error of the mean (S.E.M) and differences
were considered significant at the 95% confidence limit.
For each of the respective phases, significance was
determined by paired student t-test (p< 0.05); “n”
represents the number of preparations.Figure 1 Effects of MF on baseline heart rate, sympathetic nerve activ
baseline heart rate, sympathetic nerve and phrenic nerve activity during co
rate significantly increases due to a significant reduction in the Te duration
effects are reversed after washout. Asterisks denote significance.Mefloquine addition
Once a stable preparation had been established and
baseline autonomic reflexes had been conducted, 1 μM
MF was added directly into the perfusate. Autonomic




Preparation viability was confirmed by the presence of
rhythmic and ramping PND [15], arterial baroreceptor
or peripheral chemoreceptor mediated bradycardia, and
an increase in phrenic motor activity induced by injec-
tion of NaCN. Constant perfusion pressure during
recordings from the WHBP allowed the brainstem to re-
main adequately oxygenated.
Effects of MF on resting heart rate, sympathetic and
phrenic nerve activity
The average baseline HR was 336 ± 12 beats per minute
(bpm) which was significantly decreased by application
of MF (1 μM) to 302 ± 9.9 bpm (a 9.7% decrease; p<0.05;
n= 10). This response returned to baseline after washout
of MF (Figure 1A and B). Changes in perfusion pressure
were small and variable upon MF application, but there
were no statistically significant differences across theity and phrenic nerve activity. (A) Example, original traces showing
ntrol, MF and washout. Heart rate significantly decreases (B) and PND
(seconds) (C and D) upon the application of MF to the perfusate, the
Figure 2 MF induces bradycardia during parasympathetic
blockade with atropine. (A) Example, original traces showing
baseline heart rate, sympathetic and phrenic nerve activity and
perfusion pressure during control. (B) Addition of 1 μM atropine to
the perfusate resulted in significantly increased heart rate and
abolished respiratory sinus arrhythmia, indicative of parasympathetic
blockade. (C) MF induces a bradycardia in the presence of atropine.
(D) Average heart rate (n=4) is significantly increased from control in
the presence of atropine. In the presence of atropine MF
significantly decreased HR.
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cardia, the PND rate was increased by MF. Measure-
ments of the duration of specific respiratory phases
reveals that MF significantly decreases Te duration
(Figure 1C; p= 0.02) and significantly decreases Ttot
duration (p= 0.02) which results in an increased PND
rate (Figure 1D; p= 0.01; n= 10).
Mefloquine induced bradycardia persists upon
parasympathetic blockade
To determine if the decrease in baseline heart rate after
MF addition was due to parasympathetic stimulation,
1 μM atropine sulphate was added to the perfusate of
the rat WHBP. Consistent with parasympathetic
blockade, atropine resulted in an increase in heart rate
(from 336 ± 12 bpm in control to 387 ± 8 bpm; n= 4;
Figure 2A and B; p= 0.01) and abolished respiratory
sinus arrhythmias (Figure 2B and C). Nevertheless, in
the presence of atropine MF elicited a significant de-
crease in heart rate from 387 ± 8 bpm with atropine
alone to 351 ± 11 bpm with atropine and 1 μM MF
(Figure 2C). This was an average bradycardia of 28 ±
4 bpm (n= 4; Figure 2D; p= 0.001).
Respiratory related sympathetic activity was decreased by
Mefloquine
The strength of respiratory-related SND burst (which
could be considered a measure of the synchrony be-
tween the two systems) was significantly decreased in
MF. The ratio between the
R
SND during the first
500 ms of expiration and the
R
SND in the first 500 ms
of inspiration was 1.26 ± 0.02 in control, which
decreased by 9.7% with MF to 1.14 ± 0.01 (Figure 3A, B;
p< 0.001; n= 6).
Attenuation of chemoreceptor mediated
sympathoexcitation with MF
Chemoreceptor stimulation resulted in a pronounced
bradycardia, an increased PND rate and sympathoexcita-
tion in both control and after systemic MF application
(Figure 4A and B). After MF, chemoreceptor stimulation
resulted in a significantly enhanced PND rate increase
(Figure 4A and B). Moreover, after MF the characteristic
Figure 3 Respiratory related sympathetic bursts are attenuated
with MF. (A, top panel) respiratory related sympathetic bursts are
pronounced during control, arrows denote the peak in SND which
occurs during the post inspiratory phase of the PND cycle. (A,
bottom panel) reduction in the respiratory related
R
SND bursts with
MF, arrows denote the same post inspiratory phase of the PND cycle
that exhibited the peak
R
SND during control. (B) Ratio between theR
SND during the first 500 ms of inspiration and the first 500 ms of
post inspiration.
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increased (Figure 4D; p< 0.05, n= 6).
Chemoreceptor reflex, activated by administration of
0.1 ml of 0.03% NaCN, also resulted in a pronounced
sympathoexcitation in control, MF and recovery
(Figure 5A-C). However, the sympathoexcitation was
attenuated in the presence of MF (Figure 5B). Mean
sympathoexcitation was reduced in the presence of MF
by 51.6 ± 11.1% compared to control (p= 0.01; n= 12).
After MF washout NaCN evoked sympathoexcitation
recovered to control (Figure 5C and D).
Analysis of the respiratory related SND bursting dur-
ing the inspiratory phase and the expiratory phase of the
PND cycle revealed that with MF there was a signifi-
cantly attenuated increase in
R
SND during both inspir-
ation and expiration in comparison to control (p= 0.001;
n= 10). The mean level of integrated inspiratory
R
SND
during chemoreceptor stimulation in control increased
by 98.1 ± 13.2% from baseline values, which was attenu-
ated to an increase of 34.0 ± 7.0% from baseline values
with MF. During expiration, the mean level of
R
SND
increased by 194.13 ± 28.97% and with MF this was sig-
nificantly attenuated to a 103.0 ± 16.7% increase inR
SND upon chemoreceptor stimulation (Figure 5E).HR recovery time is increased by MF after chemoreceptor
stimulation
Chemoreceptor stimulation elicited a pronounced brady-
cardia in all conditions (control, MF and wash). How-
ever, with MF, HR recovery time (time from the initial
bradycardic response to HR returning to resting levels)
significantly increased by 21 ± 13.7% from 16.1 ± 1.5 sec-
onds to 26.1 ± 6.7 seconds (Figure 6; p< 0.05; n= 9).
Upon MF washout, the HR return time was 18.7 ±
3.3 seconds which was not significantly different to con-
trol (Figure 6A and B). The degree of NaCN induced
bradycardia was attenuated in MF. HR reduced by
66.2 ± 3.7% from baseline after NaCN administration in
control. With MF, the degree of bradycardia was attenu-
ated to a 48.9 ± 4.4% reduction (Figure 6C; p= 0.008;
n= 6). Upon MF washout, the degree of bradycardia was
73.4 ± 3.3% seconds from baseline, which was not signifi-
cantly different to control.
Figure 4 MF augments PND discharge rate increase following
chemoreceptor stimulation. (A-C) Upon chemoreceptor
stimulation (arrow) during control, MF and wash, a pronounced
sympathoexcitation in
R
SND occurs and respiratory rate increases.
Analysis of respiratory variables reveals no significantly different
increase in Ti, Te or Ttot duration from baseline however, the PND
rate significantly increased with MF compared to control and wash
(D). Asterisks denote significance, NS; not significant.
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pressure does not change with MF
MF has no significant effect on baroreceptor reflex sen-
sitivity to increased perfusion pressure, expressed as the
change in HR rate (bpm) per 1 mmHg change in perfu-
sion pressure, from control values of 2.27 ± 0.21 bpm ×
mmHg-1 to 2.93 ± 0.76 bpm × mmHg-1 (Figure 7A and
B; p= 0.14; n= 6). In addition, the degree of sympathoin-
hibition after baroreceptor stimulation was no different
with MF in comparison to control (Figure 7C; p= 0.12;
n= 15). The mean inspiratory related
R
SND during baro-
receptor stimulation decreased by 24.3 ± 4.3% in control
and by 49.3 ± 7.5% with MF from baseline values. The
mean expiratory related
R
SND decreased by 60.59 ±
4.40% in control and by 55.5 ± 7.3% with MF from base-
line values. These changes from baseline values were not
significantly different from control with MF (Figure 7E).
Changes in respiratory parameters upon baroreceptor
stimulation revealed that the average decrease in Ti dur-
ation was attenuated with MF and this also resulted in
attenuation of the average PND rate increase with MF
(Figure 7D; p= 0.02; n= 15) which returned to control
upon washout. Therefore, an attenuated increase in re-
spiratory parameters in response to baroreceptor stimu-
lation in MF was observed.Discussion
This study shows that the application of MF to the per-
fusate of an arterially perfused, non-anaesthetised rat
WHBP influences cardio-respiratory drive. MF resulted
in a decrease in resting HR, decreased respiratory-
related SND bursts, attenuation of the chemoreceptor-
mediated sympathoexcitation, decreased rate of return
to resting HR rate following chemoreceptor induced
bradycardia and increased PND rate.
In this study MF was applied at 1 μM, which is at
the lower end of the range detected in the plasma
levels of patients taking MF as an anti-malarial drug
[16]. The site of action of MF at this concentration
may be peripheral or central, since it crosses the blood
brain barrier [17]. The cardiovascular effects observed
here suggest at least one route of action of MF is on
central sympathetic drive, since direct recordings from
the sympathetic chain revealed a reduced degree of
Figure 5 Sympathoexcitation is attenuated with MF. (A) Sympathoexcitation elicited by NaCN (arrows) during control (A), with MF (B) and
after washout (C). Sympathoexcitation is attenuated with MF, this effect is reversed upon washout (D) (n = 12). Sympathoexcitation in all
conditions is accompanied by increased PND rate. (E) Analysis of the respiratory related sympathetic bursts reveals the increase in
R
SND upon
chemoreceptor stimulation is significantly attenuated during both the inspiratory and expiratory phase of the PND cycle in comparison to
control. (Values are normalised from baseline values at 100%). Asterisks denote significance; NS: not significant.
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response to peripheral chemoreceptor activation. Fur-
thermore, since previous studies have excluded a direct
effect of MF on the QPRS interval [4], the observation
of a delayed return to resting HR after chemoreceptor
activation is indicative of effects on sympathetic out-
flow rather than on the heart itself.
Mefloquine induced bradycardia appears not to be
mediated via parasympathetic pathways
Whilst exerting inhibitory influences on sympathetic
outflow and eliciting a resting bradycardia, MF appears
not to significantly influence parasympathetic outflow.
Direct evidence was obtained as the MF induced brady-
cardia persisted during parasympathetic blockade in the
presence of atropine. This was confirmed indirectly since
baroreceptor reflex gain in the presence of MF was no
different to control. In addition, the magnitude of
chemoreceptor mediated bradycardia was attenuated in
the presence of MF, suggesting that MF did not enhance
vagal response to the chemoreceptor stimulus. The
principle effect of MF as measured here therefore
appears to be a reduced sympathetic nervous activity.
Does Mefloquine act on Cx36 containing gap junctions in
the CNS to reduce central sympathetic drive?
One potential mechanism for the MF influence on cen-
tral sympathetic drive is through its well establisheduncoupling of Cx36-containing GJs [8]. The concen-
tration of MF used here (1 μM) blocks 90% of the
current mediated by Cx36 containing GJs when they
are expressed in N2A cell lines [8] and does not
affect any other connexins expressed in cardiovascular
tissue [8].
Indeed, Cx36 immunoreactivity has been reported on
sympathetic preganglionic neurones (SPNs) in the
intermediolateral cell column (IML) of the rat spinal
cord [18]. Electrophysiological studies have revealed
that GJs participate in communication between SPNs
[10,19]. Further, rhythmic activity recorded from the
IML, the spinal nucleus containing SPNs, is reduced
with the broad spectrum GJ blocker carbenoxolone
(CBX) and can be abolished by MF [20]. Results from
these experiments are consistent with effects of MF
acting through Cx36 containing gap junctions. For ex-
ample, the delayed return to resting HR following
chemoreceptor stimulation suggests that the sympa-
thetic pathways that would normally restore resting HR
levels have been compromised with MF mediated
blockade of Cx36 containing GJs.
However, based on the current study other sites of
action of MF cannot be ruled out. For example, sym-
pathetic outflow is influenced by inputs from the
rostral ventrolateral medulla [21-23] whilst both
chemoreceptor and baroreceptor afferents terminate
in the nucleus of the tractus solitarius. Both these
Figure 6 HR recovery time following chemoreceptor stimulation is increased by MF. (A) Heart rate (bpm, beats per minute) upon
chemoreceptor stimulation (closed arrow) during control, MF and washout. With MF the heart rate takes longer to return to resting levels upon
chemoreceptor stimulation (open arrow). (B) Average heart rate recovery time upon chemoreceptor stimulation is increased with MF compared
to control and washout. Asterisks denote significance, NS; not significant.
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could also be sites of action for the MF in this study.
Regardless of the site of action, our data show clear
decreases in respiratory-related sympathetic activity in
the presence of MF which suggests an uncoupling of the
normal tight synchronization of respiratory and sympa-
thetic outflows.Augmented respiratory drive with Mefloquine
In the current study, MF decreased the time for expir-
ation (Te) during baseline recordings as well as more
pronounced alterations in respiratory variables in re-
sponse to chemoreceptor and baroreceptor activation.
The potential that MF is acting on Cx36 to influence re-
spiratory outflow is consistent with previous evidence
Figure 7 (See legend on next page.)
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Figure 7 Baroreflex sensitivity and sympathoinhibition upon baroreceptor stimulation in MF is not significantly different from control.
Stimulating the baroreceptors, with a transient increase in perfusion pressure (arrows), resulted in a reflex bradycardia (A). Upon application of MF
to the perfusate, there was no significant change in baroreflex sensitivity (A and B) or the extent of sympathoinhibition from control (C). Upon
baroreceptor stimulation the PND rate increase is significantly attenuated in comparison to control (D) due to the significantly attenuated
reduction in Ti duration. (E) Analysis of the respiratory related sympathetic bursts in MF reveals no significant difference in the degree of
sympathoinhibition in
R
SND upon baroreceptor stimulation during both the inspiratory and expiratory phase of the PND cycle in comparison to
control. Asterisks denote significance, NS; not significant.
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to be expressed throughout brainstem respiratory
regions and coupled activity has been reported in these
regions [9,25-27]. Indeed, in the in situWHBP of the rat
systemic application of GJ blockers such as heptanol,
CBX and halothane reversibly decreased respiratory fre-
quency via an increase in expiration duration [28], al-
though these are all broad spectrum GJ blockers. Further,
uncoupling brainstem GJs, using CBX, octanol or hepta-
nol, in in situ WHBP increased respiratory burst fre-
quency and decreased peak amplitude of integrated
PND. In addition, PND became “bell shaped” instead of
ramping with gap junctional blockade [29]. However, in
contrast to the findings of [29] but in agreement with the
current findings, Rodman et al., (2006) found that block-
ing GJs in the WHBP by CBX and octanol produced in-
consistent effects, but that eupneic or gasping rhythms
persisted. Similarly, using the more specific GJ blocker
MF did not change the eupneic shape of the PND in the
current study. However, MF evoked a decrease in Te,
suggesting that Cx36 containing GJs may play a role in
modulating the respiratory frequency. It may be that
more than one type of GJ may be involved in respiratory
rhythm generation – indeed both connexin 32 and 26 are
expressed in PreBotzinger complex and chemosensitive
brainstem regions [25,30]. Whilst the effects of MF in
this study are consistent with a role for Cx36 GJs in car-
diorespiratory control, future studies could perhaps
examine this more specifically using Cx36 knockout
mice.
Clinical relevance/physiological implications of the study
MF has been a widely used anti-malarial drug with mod-
erate to severe neurological side effects that include
headache, strange or vivid dreams, dizziness, anxiety,
and sleeplessness [31,32] as well as more severe neuro-
psychiatric adverse events such as psychosis and bipolar
disorder [33]. A recent study also indicates that MF
induces motor learning deficits in humans, which were
associated with blockade of the known Cx36 mediated
GJs in the inferior olive [34]. This current study suggests
that unintended actions on autonomic and respiratory
systems may also be a consideration. Indeed, there are
already indications of such side effects since bradycardia
and arrhythmia have been reported in some patientstaking MF [4]. In particular, the reduced response to
chemoreceptor challenge may have implications for MF
administration prior to and during activities such as
mountain climbing and diving, where chemoreceptor ac-
tivation may occur. An in depth study of the effects of
MF on sympathetic activity in humans, perhaps using
microneurography to record sympathetic activity [35],
therefore appears warranted.
Conclusions
Application of MF to the WHBP of the rat revealed sig-
nificant alterations in autonomic and respiratory activity.
Further, the use of MF as an anti-malarial may require
careful consideration in some populations.
Abbreviations
aCSF: Artificial cerebrospinal fluid; Cx36: Connexin 36;
ECG: Electrocardiography; GJ: Gap junction; HR: Heart rate;
IML: Intermediolateral cell column; MF: Mefloquine; NaCN: Sodium cyanide;
PND: Phrenic nerve discharge; SND: Sympathetic nerve discharge;
SPN: Sympathetic preganglionic neurone; WHBP: Working heart brainstem
preparation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VKL completed the experimental study and the paper was written with
equal contribution from VKL, JD and SAD. MD provided supervision of VKL
with the WHBP and commented on the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
Supported by a BBSRC studentship to VKL and the British Heart Foundation
(Project number PG/08/120/26338; SAD, JD).
Received: 27 July 2012 Accepted: 8 December 2012
Published: 15 December 2012
References
1. Karbwang J, White NJ: Clinical pharmacokinetics of mefloquine.
Clin Pharmacokinet 1990, 19:264–279.
2. Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf 2004,
27:25–61.
3. Ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD,
Chongsuphajaisiddhi T, et al: High-dose mefloquine in the treatment of
multidrug-resistant falciparum malaria. J Infect Dis 1992, 166:1393–1400.
4. Laothavorn P, Karbwang J, Na BK, Bunnag D, Harinasuta T: Effect of
mefloquine on electrocardiographic changes in uncomplicated
falciparum malaria patients. Southeast Asian J Trop Med Public Health 1992,
23:51–54.
5. Bhanji A, Atkins C, Karim M: Postural orthostatic tachycardia syndrome: a
case report of palpitations and dizziness following prophylactic
mefloquine use. Int J Clin Pharmacol Ther 2010, 48:577–581.
Lall et al. Journal of Biomedical Science 2012, 19:103 Page 11 of 11
http://www.jbiomedsci.com/content/19/1/1036. Udry E, Bailly F, Dusmet M, Schnyder P, Lemoine R, Fitting JW: Pulmonary
toxicity with mefloquine. Eur Respir J 2001, 18:890–892.
7. Saleri N, Gulletta M, Matteelli A, Caligaris S, Tomasoni LR, Antonini B, et al:
Acute respiratory distress syndrome in Plasmodium vivax malaria in
traveler returning from Venezuela. J Travel Med 2006, 13:112–113.
8. Cruikshank SJ, Hopperstad M, Younger M, Connors BW, Spray DC, Srinivas
M: Potent block of Cx36 and Cx50 gap junction channels by mefloquine.
Proc Natl Acad Sci U S A 2004, 101:12364–12369.
9. Rekling JC, Shao XM, Feldman JL: Electrical coupling and excitatory
synaptic transmission between rhythmogenic respiratory neurons in the
preBotzinger complex. J Neurosci 2000, 20:RC113.
10. Logan SD, Pickering AE, Gibson IC, Nolan MF, Spanswick D: Electrotonic
coupling between rat sympathetic preganglionic neurones in vitro.
J Physiol 1996, 495(Pt 2):491–502.
11. Nolan MF, Logan SD, Spanswick D: Electrophysiological properties of
electrical synapses between rat sympathetic preganglionic neurones
in vitro. J Physiol 1999, 519(Pt 3):753–764.
12. Spanswick D, Logan SD: Spontaneous rhythmic activity in the
intermediolateral cell nucleus of the neonate rat thoracolumbar spinal
cord in vitro. Neuroscience 1990, 39:395–403.
13. Wentlandt K, Samoilova M, Carlen PL, El Beheiry H: General anesthetics
inhibit gap junction communication in cultured organotypic
hippocampal slices. Anesth Analg 2006, 102:1692–1698.
14. Simms AE, Paton JF, Pickering AE: Hierarchical recruitment of the
sympathetic and parasympathetic limbs of the baroreflex in
normotensive and spontaneously hypertensive rats. J Physiol 2007,
579:473–486.
15. Potts JT, Spyer KM, Paton JF: Somatosympathetic reflex in a working
heart-brainstem preparation of the rat. Brain Res Bull 2000, 53:59–67.
16. Simpson JA, Price R, ter KF, Teja-Isavatharm P, Nosten F,
Chongsuphajaisiddhi T, et al: Population pharmacokinetics of mefloquine
in patients with acute falciparum malaria. Clin Pharmacol Ther 1999,
66:472–484.
17. Baudry S, Pham YT, Baune B, Vidrequin S, Crevoisier C, Gimenez F, et al:
Stereoselective passage of mefloquine through the blood–brain barrier
in the rat. J Pharm Pharmacol 1997, 49:1086–1090.
18. Marina N, Becker DL, Gilbey MP: Immunohistochemical detection of
connexin36 in sympathetic preganglionic and somatic motoneurons in
the adult rat. Auton Neurosci 2008, 139:15–23.
19. Nolan MF, Gibson IC, Logan SD: Actions of the anaesthetic Saffan on rat
sympathetic preganglionic neurones in vitro. Br J Pharmacol 1997,
121:324–330.
20. Pierce ML, Deuchars J, Deuchars SA: Spontaneous rhythmogenic
capabilities of sympathetic neuronal assemblies in the rat spinal cord
slice. Neuroscience 2010, 170:827–838.
21. Dampney RA, Goodchild AK, Robertson LG, Montgomery W: Role of
ventrolateral medulla in vasomotor regulation: a correlative anatomical
and physiological study. Brain Res 1982, 249:223–235.
22. Nakamura K, Matsumura K, Hubschle T, Nakamura Y, Hioki H, Fujiyama F,
et al: Identification of sympathetic premotor neurons in medullary raphe
regions mediating fever and other thermoregulatory functions. J Neurosci
2004, 24:5370–5380.
23. Strack AM, Sawyer WB, Hughes JH, Platt KB, Loewy AD: A general pattern
of CNS innervation of the sympathetic outflow demonstrated by
transneuronal pseudorabies viral infections. Brain Res 1989, 491:156–162.
24. Solomon IC: Connexin36 distribution in putative CO2-chemosensitive
brainstem regions in rat. Respir Physiol Neurobiol 2003, 139:1–20.
25. Solomon IC, Halat TJ, El Maghrabi R, O’Neal MH III: Differential expression
of connexin26 and connexin32 in the pre-Botzinger complex of
neonatal and adult rat. J Comp Neurol 2001, 440:12–19.
26. Bou-Flores C, Berger AJ: Gap junctions and inhibitory synapses modulate
inspiratory motoneuron synchronization. J Neurophysiol 2001,
85:1543–1551.
27. Elsen FP, Shields EJ, Roe MT, Vandam RJ, Kelty JD: Carbenoxolone induced
depression of rhythmogenesis in the pre-Botzinger Complex.
BMC Neurosci 2008, 9:46.
28. Rodman JR, Harris MB, Rudkin AH, St John WM, Leiter JC: Gap junction
blockade does not alter eupnea or gasping in the juvenile rat.
Respir Physiol Neurobiol 2006, 152:51–60.29. Solomon IC, Chon KH, Rodriguez MN: Blockade of brain stem gap
junctions increases phrenic burst frequency and reduces phrenic burst
synchronization in adult rat. J Neurophysiol 2003, 89:135–149.
30. Solomon IC, Halat TJ, El Maghrabi MR, O’Neal MH III: Localization of
connexin26 and connexin32 in putative CO(2)-chemosensitive brainstem
regions in rat. Respir Physiol 2001, 129:101–121.
31. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E,
et al: Tolerability of malaria chemoprophylaxis in non-immune travellers
to sub-Saharan Africa: multicentre, randomised, double blind, four arm
study. BMJ 2003, 327:1078.
32. van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ,
Overbosch D, et al: Neuropsychiatric events during prophylactic use of
mefloquine before travelling. Eur J Clin Pharmacol 2002, 58:441–445.
33. Toovey S: Mefloquine neurotoxicity: a literature review. Travel Med Infect
Dis 2009, 7:2–6.
34. van Essen TA, van der Giessen RS, Koekkoek SK, Vanderwerf F, Zeeuw CI,
van Genderen PJ, et al: Anti-malaria drug mefloquine induces motor
learning deficits in humans. Front Neurosci 2010, 4:191.
35. Yucha CB: Use of microneurography to evaluate sympathetic activity in
hypertension: a brief review. Appl Psychophysiol Biofeedback 2000,
25:55–63.
doi:10.1186/1423-0127-19-103
Cite this article as: Lall et al.: The anti-malarial drug Mefloquine disrupts
central autonomic and respiratory control in the working heart
brainstem preparation of the rat. Journal of Biomedical Science 2012
19:103.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
